Skip to content
Medical Health Aged Care

Preventive Mental Health Conference aims to shift debate from niche to the mainstream

Public Health Association of Australia < 1 min read

23 March 2026

 

Experts from across Australia and overseas will gather in Parramatta from tomorrow to present research, share ideas, and work together to promote and protect the mental health and wellbeing of people across the country.

Organised by the Public Health Association and Prevention United, the Preventive Mental Health Conference runs 24-25 March at the Novotel Parramatta.

Media are welcome to attend, and various presenters are available for interview.

Speakers will include Commissioner Dr Angela Jackson from the Productivity Commission, Everymind’s Director, Dr Jaelea Skehan OAM, and Associate Professor Clinton Schultz, Director First Nations Strategy and Partnerships at the Black Dog Institute.

The program is available here. Plenary session topics include:

 

WHAT: Preventive Mental Health Conference

WHEN: 9am-5pm, Tue 24 and Wed 25 March 2026

WHERE: Novotel Parramatta, 350 Church St, Parramatta, Dharug Country, NSW

WHO: Public Health Association and Prevention United

 

For further information/comment:

Paris Lord (he/him), PHAA Communications & Media Manager, 0478 587 917, [email protected]

 

Hollie Harwood, PHAA Strategic Communications Adviser, 0400 762 010, [email protected]

 

 

 

About the Public Health Association of Australia

We’re Australia's peak body for public health and advocate for the health and wellbeing of everyone. We strive to help prevent – rather than cure – illness and disease. We represent around 2,000 individual members from more than 40 professional groups interested in the promotion of public health. We have branches in every state and territory. More at https://www.phaa.net.au/


Contact details:

Paris Lord (he/him), PHAA Communications & Media Manager, 0478 587 917, [email protected]

 

Hollie Harwood, PHAA Strategic Communications Adviser, 0400 762 010, [email protected]

 

Media

More from this category

  • Medical Health Aged Care
  • 16/06/2026
  • 22:47
Optimi Health Corp.

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studiesNew microdose formats extend Optimi's psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant depression in Australia under the country's Authorized Prescriber SchemeVANCOUVER, British Columbia, June 16, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage GMP pharmaceutical manufacturer of regulated psychedelic drug products, today announced it has completed production of two microdose psilocybin finished drug products, formulated at 1 mg and 2 mg dosages. The products…

  • Medical Health Aged Care
  • 16/06/2026
  • 14:30
Dementia Australia

Brisbane comes together for people impacted by dementia

Brisbane community members tied up their laces and showed up in force last weekend for the 2026 Brisbane Memory Walk & Jog - throwing their support behind people impacted by dementia whilst getting active to improve their brain health. More than 1,470 people walked, ran and jogged to the finish line to raise an impressive total of $195,098. Dementia Australia CEO Professor Tanya Buchanan extended her gratitude to all who participated, volunteered and raised vital funds for the cause. “There was an incredible turnout from the Brisbane community this year yet again, in support of the many people impacted by…

  • Contains:
  • Biotechnology, Medical Health Aged Care
  • 16/06/2026
  • 09:51
ENA Respiratory

ENA Respiratory Receives USPTO Notice of Allowance for Two Patents Covering TLR2 Agonists and Rhinovirus-Mediated COPD Exacerbations

Melbourne, Australia, 15 June 2026 – ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, announces today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for two patent applications notably a composition-of-matter patent and method-of-use for its Toll-like receptor 2 (TLR2) therapies. A composition-of-matter patent (US 17/622,451, "A series of TLR2 agonist compounds") and A method-of-use patent for the treatment of rhinovirus-mediated exacerbations of chronic obstructive pulmonary disease (COPD) (US 16/495,829, "Methods of treating rhinovirus-mediated exacerbations of COPD…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.